BeOne Medicines Ltd. – Sponsored ADR $ONC Shares Bought by Russell Investments Group Ltd.

Russell Investments Group Ltd. increased its position in BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Free Report) by 34.2% in the 3rd quarter, HoldingsChannel reports. The fund owned 29,621 shares of the company’s stock after buying an additional 7,556 shares during the quarter. Russell Investments Group Ltd.’s holdings in BeOne Medicines were worth $10,839,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Jefferies Financial Group Inc. raised its position in BeOne Medicines by 184.4% during the third quarter. Jefferies Financial Group Inc. now owns 18,200 shares of the company’s stock valued at $6,660,000 after purchasing an additional 11,800 shares in the last quarter. Knights of Columbus Asset Advisors LLC acquired a new stake in shares of BeOne Medicines in the 3rd quarter valued at $106,000. Allspring Global Investments Holdings LLC boosted its holdings in shares of BeOne Medicines by 22.6% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 966 shares of the company’s stock valued at $340,000 after purchasing an additional 178 shares in the last quarter. Hager Investment Management Services LLC acquired a new stake in shares of BeOne Medicines in the 3rd quarter valued at $891,000. Finally, Ethic Inc. acquired a new stake in shares of BeOne Medicines in the 3rd quarter valued at $218,000. Institutional investors own 48.55% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. TD Cowen boosted their price target on BeOne Medicines from $424.00 to $454.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. China Intl Cap began coverage on BeOne Medicines in a research report on Friday, November 6th. They set a “strong-buy” rating on the stock. Weiss Ratings raised BeOne Medicines from a “buy (b-)” rating to a “buy (b)” rating in a report on Monday. Wells Fargo & Company lifted their target price on shares of BeOne Medicines from $400.00 to $435.00 and gave the stock an “overweight” rating in a research report on Friday, November 6th. Finally, Citigroup reissued an “outperform” rating on shares of BeOne Medicines in a research note on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $441.64.

Read Our Latest Report on BeOne Medicines

BeOne Medicines Stock Performance

NASDAQ:ONC opened at $390.94 on Friday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 3.55. BeOne Medicines Ltd. – Sponsored ADR has a fifty-two week low of $253.95 and a fifty-two week high of $424.73. The company has a 50 day simple moving average of $374.57 and a two-hundred day simple moving average of $329.78. The company has a market capitalization of $42.92 billion, a PE ratio of 49.97 and a beta of 0.63.

BeOne Medicines (NASDAQ:ONC – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported $3.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.34 by $1.30. BeOne Medicines had a net margin of 13.86% and a return on equity of 19.04%. The firm had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.76 billion. Research analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 9.98 earnings per share for the current year.

Insider Activity

In related news, insider Xiaodong Wang sold 38,287 shares of BeOne Medicines stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $349.10, for a total transaction of $13,365,991.70. Following the completion of the transaction, the insider owned 6,079 shares of the company’s stock, valued at $2,122,178.90. This trade represents a 86.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Xiaobin Wu sold 280 shares of the business’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $380.00, for a total transaction of $106,400.00. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 135,571 shares of company stock worth $48,487,792 over the last ninety days. Corporate insiders own 6.19% of the company’s stock.

BeOne Medicines Company Profile

(Free Report)

BeOne Medicines, formerly known as BeiGene, is a global biotechnology company focused on discovering, developing, manufacturing and commercializing cancer medicines. Founded in Beijing in 2010, the company has expanded its research and commercial operations across multiple regions, including the United States, Europe and Asia. Its marketed products include Brukinsa (zanubrutinib), a targeted therapy for certain blood cancers, and Tevimbra (tislelizumab), an immunotherapy used to treat several types of cancer.

Further Reading

Want to see what other hedge funds are holding ONC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Free Report).

Institutional Ownership by Quarter for BeOne Medicines (NASDAQ:ONC)

Receive News & Ratings for BeOne Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeOne Medicines and related companies with MarketBeat.com's FREE daily email newsletter.